Gamma polyglutamated pemetrexed and uses thereof

Patent metadata

Field	Value
Publication number	US-12246018-B2
Application number	US-201916967234-A
Country	US
Kind code	B2
Filing date	Feb 7, 2019
Priority date	Feb 7, 2018
Publication date	Mar 11, 2025
Grant date	Mar 11, 2025

Abstract

The disclosure relates generally to gamma polyglutamated pemetrexed compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated pemetrexed, and methods of making and using the gamma polyglutamated pemetrexed compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).

First claim

What is claimed is:

1. A liposomal composition comprising a gamma polyglutamated pemetrexed encapsulated by a liposome, wherein the gamma polyglutamated pemetrexed has 4, 5, 2-10, 4-6, or more than 5, glutamyl groups having a gamma carboxyl group linkage, and wherein the liposome is pegylated, wherein the liposome does not contain a targeting moiety having specific affinity for a surface antigen on a target cell,
wherein the liposome does not contain a cell penetrating peptide and does not contain a mitochondria penetrating peptide,
wherein the liposome has a zeta potential that is less than or equal to zero, between 0 to −150 mV, or between −30 to −50 mV, and

wherein the liposome is capable of delivering the gamma polyglutamated pemetrexed directly into a cell.

2. The liposomal composition of claim 1 , wherein
(a) the gamma polyglutamated pemetrexed comprises two or more glutamyl groups in the L-form having gamma carboxyl group linkages,
(b) each of the glutamyl groups of the gamma polyglutamated pemetrexed is in the L-form and has a gamma carboxyl group linkage,
(c) at least one of the glutamyl groups of the gamma polyglutamated pemetrexed is in the D-form and has a gamma carboxyl group linkage, or
(d) the gamma polyglutamated pemetrexed comprises two or more glutamyl groups in the L-form and at least one glutamyl group in the D-form having gamma carboxyl group linkages.

3. The liposomal composition of claim 1 , wherein the liposome further comprises one or more nonpolyglutamated polyglutamatable antifolate or non-polyglutamatable antifolate.

4. The liposomal composition of claim 1 , wherein the wherein the gamma polyglutamated pemetrexed contains 4, 5, 2-10, or 4-6 glutamyl groups.

5. The liposomal composition of claim 1 , wherein the gamma polyglutamated pemetrexed is gamma tetraglutamated pemetrexed.

6. The liposomal composition of claim 1 , wherein the gamma polyglutamated pemetrexed is gamma pentaglutamated pemetrexed.

7. The liposomal composition of claim 1 , wherein the gamma polyglutamated pemetrexed is gamma hexaglutamated pemetrexed.

8. The liposomal composition of claim 1 , wherein the liposome has a diameter in the range of 20 nm to 500 nm, 20 nm to 200 nm, or 80 nm to 120 nm.

9. The liposomal composition of claim 1 , wherein the liposome is formed from liposomal components comprising:
at least one of an anionic lipid and a neutral lipid; or
at least one selected from: DSPE; DSPE-PEG; HSPC; HSPC-PEG; cholesterol; cholesterol-PEG; and DSPE-PEG-FITC.

10. The liposomal composition of claim 1 , wherein one or more liposomal components further comprises at least one steric stabilizer selected from: poly (vinyl pyrrolidone) (PVP); poly (acrylamide) (PAA); poly (2-methyl-2-oxazoline); poly (2-ethyl-2-oxazoline); phosphatidyl polyglycerol; poly [N-(2-hydroxypropyl) methacrylamide]; amphiphilic poly-N-vinylpyrrolidones; L amino-acid-based polymer; oligoglycerol, copolymer containing polyethylene glycol and polypropylene oxide, Poloxamer 188, and polyvinyl alcohol.

11. The liposomal composition of claim 1 , wherein the PEG has a number average molecular weight (Mn) of 200 to 5000 daltons.

12. The liposomal composition of claim 1 , wherein the liposome is in an aqueous pharmaceutically acceptable carrier comprising:
a tonicity agent at a concentration of greater than 1%;
1% to 50% trehalose;
1% to 50% dextrose;
5% dextrose suspended in an HEPES buffered solution; or
a total concentration of sodium acetate and calcium acetate of between 50 mM to 500 mM.

13. The liposomal composition of claim 1 , wherein the interior space of the liposome has a pH of 5-8 or a pH of 6-7, or any range therein between.

14. The liposomal composition of claim 1 , wherein the liposome comprises between 10 to 500,000, between 10 to 200,000, or between 10 to 100,000 molecules of the gamma polyglutamated pemetrexed, or any range therein between.

15. The liposomal composition of claim 1 , which further comprises at least one cryoprotectant selected from mannitol, trehalose, sorbitol, and sucrose.

16. The liposomal composition of claim 1 , which further comprises carboplatin or pembrolizumab.

17. The liposomal composition of claim 16 , wherein the nonpolyglutamated polyglutamatable antifolate is selected from: pralatrexate, methotrexate, pemetrexed, lometrexol, raltitrexed, pralatrexate, and aminopterin; or the non-polyglutamatable antifolate is selected from: trimetrexate, piritrexim, talotrexin, nolatrexed, and plevitrexed.

18. The liposomal composition of claim 1 , wherein the gamma polyglutamated pemetrexed has 4-6 glutamyl groups having a gamma carboxyl group linkage, and wherein the liposome has a diameter in the range of 20 nm to 200 nm.

19. A pharmaceutical composition comprising the liposomal composition of claim 1 .

20. A method of killing a hyperproliferative cell that comprises contacting a hyperproliferative cell with the liposomal composition of claim 1 .

21. A method comprising administering an amount of the liposomal composition of claim 1 to a subject having cancer, wherein the amount of the liposomal composition is effective for killing a cancer cell.

22. The method of claim 21 , wherein the cancer is a non-hematologic malignancy.

23. The method of claim 22 , wherein the non-hematologic malignancy is selected from the group consisting of lung cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, head and neck cancer, gastric cancer, gastrointestinal cancer, colon cancer, colorectal cancer, esophageal cancer, cervical cancer, liver cancer, kidney cancer, biliary duct cancer, gallbladder cancer, bladder cancer, sarcoma, brain cancer, central nervous system cancer, and melanoma.

24. The method of claim 21 , wherein the cancer is a hematologic malignancy.

25. The method of claim 24 , wherein the hematologic malignancy is selected from a leukemia, a lymphoma a myeloma and a plasma cell dyscrasia.

26. A method of preparing a gamma polyglutamated pemetrexed composition comprising the liposomal composition of claim 1 , the method comprising: forming a mixture comprising: liposomal components and gamma polyglutamated pemetrexed in solution; homogenizing the mixture to form liposomes in the solution; and processing the mixture to form liposomes containing gamma polyglutamated pemetrexed.

Assignees

• L E A F Holdings Group Llc

Inventors

• Niyikiza Clet
• Moyo Victor Mandla

Classifications

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K31/282

  Platinum compounds · CPC title

• A61K9/1277

  Preparation processes; Proliposomes · CPC title

• A61K9/1271

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title